Report overview
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
This report contains market size and forecasts of Hormone Refractory Prostate Cancer in Global, including the following market information:
Global Hormone Refractory Prostate Cancer Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hormone Refractory Prostate Cancer market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Chemotherapy Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hormone Refractory Prostate Cancer include Astellas Inc, Sanofi S.A, Dendreon Corporation, Bayer AG and Johnson & Johnson, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hormone Refractory Prostate Cancer companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hormone Refractory Prostate Cancer Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hormone Refractory Prostate Cancer Market Segment Percentages, by Type, 2021 (%)
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Global Hormone Refractory Prostate Cancer Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hormone Refractory Prostate Cancer Market Segment Percentages, by Application, 2021 (%)
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
Global Hormone Refractory Prostate Cancer Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hormone Refractory Prostate Cancer Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hormone Refractory Prostate Cancer revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hormone Refractory Prostate Cancer revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
